ALEBUND
礼 邦 医 药

Alebund Pharmaceuticals (Jiangsu) Limited
禮邦醫藥(江蘇)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 09637)

POSITIVE PROFIT ALERT
FOR THE SIX MONTHS ENDED JUNE 30, 2026

This announcement is made by Alebund Pharmaceuticals (Jiangsu) Limited (the "**Company**," together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the Board's preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the "**Reporting Period**") and the information currently available to the Board, the Group expects to record for the Reporting Period:

- revenue of approximately RMB103 million to RMB106 million, representing an increase of approximately 750% to 775% as compared with approximately RMB12.1 million for the six months ended June 30, 2025 (the "**Corresponding Period**"); and

- a loss for the period of approximately RMB158 million to RMB178 million, representing a decrease of approximately 15% to 25% as compared with approximately RMB209.7 million for the Corresponding Period.

The expected changes set out above were primarily attributable to: (i) an increase in revenue, driven by the licensing revenue recognized under the licensing and equity agreements entered into with R1 Therapeutics in respect of AP306 and growth in sales of Mircera®; and (ii) the termination of the redemption obligation on certain shares of the Company prior to the Listing (which is one-off in nature), as a result of which no related interest was accrued during the Reporting Period, narrowing the loss.

The information contained in this announcement is a preliminary assessment made by the Board based on the unaudited consolidated management accounts of the Group and the information currently available to the Board. It has not been audited or reviewed by the Company's auditor or by the audit committee of the Board and does not constitute a profit forecast. The Company expects to publish its interim results announcement for the Reporting Period in August 2026, and Shareholders and potential investors are advised to read it carefully when it is published.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
Chairman of the Board, executive Director and Chief Executive Officer

Hong Kong, August 6, 2026

As of the date of this announcement, the Board comprises (i) Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; (ii) Dr. Lu An as a non-executive Director; and (iii) Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.